Vitamin E in the prevention of vancomycin-induced nephrotoxicity.
Acute kidney injury
Nephrotoxicity
Vancomycin
Vitamin E
Journal
Research in pharmaceutical sciences
ISSN: 1735-5362
Titre abrégé: Res Pharm Sci
Pays: Iran
ID NLM: 101516968
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
14
12
2019
revised:
19
01
2020
accepted:
29
04
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
The use of vancomycin, as a key therapeutic choice for treatment of hazardous infections, may be associated with nephrotoxicity. The proposed mechanism is the indirect production of reactive oxygen species and oxidative stress. The purpose of this study was to investigate the effect of vitamin E as an antioxidant agent in the prevention of vancomycin-induced nephrotoxicity. In a matched-groups interventional study, patients who received vancomycin for any indication were assigned to vitamin E ( Treatment with vitamin E for 10 days resulted in a significant reduction of BUN (from 17.5 ± 7.8 mg/dL at baseline to 11.4 ± 4.8 mg/dL at the end; This study showed the beneficial effect of add-on therapy of vitamin E besides vancomycin in reducing AKI, which could be considered as a new potential prophylactic therapy for vancomycin-induced nephrotoxicity.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
The use of vancomycin, as a key therapeutic choice for treatment of hazardous infections, may be associated with nephrotoxicity. The proposed mechanism is the indirect production of reactive oxygen species and oxidative stress. The purpose of this study was to investigate the effect of vitamin E as an antioxidant agent in the prevention of vancomycin-induced nephrotoxicity.
EXPERIMENTAL APPROACH
METHODS
In a matched-groups interventional study, patients who received vancomycin for any indication were assigned to vitamin E (
FINDINGS / RESULTS
UNASSIGNED
Treatment with vitamin E for 10 days resulted in a significant reduction of BUN (from 17.5 ± 7.8 mg/dL at baseline to 11.4 ± 4.8 mg/dL at the end;
CONCLUSION AND IMPLICATIONS
CONCLUSIONS
This study showed the beneficial effect of add-on therapy of vitamin E besides vancomycin in reducing AKI, which could be considered as a new potential prophylactic therapy for vancomycin-induced nephrotoxicity.
Identifiants
pubmed: 32582353
doi: 10.4103/1735-5362.283813
pii: RPS-15-137
pmc: PMC7306246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
137-143Informations de copyright
Copyright: © 2020 Research in Pharmaceutical Sciences.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest for this study.
Références
Biol Pharm Bull. 2003 Jun;26(6):876-9
pubmed: 12808304
Clin Infect Dis. 2009 Aug 1;49(3):325-7
pubmed: 19569969
Am J Kidney Dis. 2010 Apr;55(4):622-7
pubmed: 20338463
Res Pharm Sci. 2019 Feb;14(1):84-92
pubmed: 30936936
Food Chem Toxicol. 2014 Aug;70:185-90
pubmed: 24857817
Toxicology. 2005 Feb 14;207(2):169-77
pubmed: 15596248
Clin Pharmacol Ther. 2017 Sep;102(3):459-469
pubmed: 28474732
Am J Med. 2010 Feb;123(2):182.e1-7
pubmed: 20103028
J Appl Toxicol. 2004 Jan-Feb;24(1):27-35
pubmed: 14745844
Clin Chim Acta. 2007 Jan;375(1-2):82-6
pubmed: 16889761
Exp Toxicol Pathol. 2012 Mar;64(3):149-53
pubmed: 20832269
Bull World Health Organ. 2001;79(4):373-4
pubmed: 11357217
Basic Clin Pharmacol Toxicol. 2007 May;100(5):328-33
pubmed: 17448119
Eur J Clin Pharmacol. 2012 Sep;68(9):1243-55
pubmed: 22411630
Intensive Care Med. 2013 Feb;39(2):165-228
pubmed: 23361625
Eur J Clin Pharmacol. 2013 Apr;69(4):747-54
pubmed: 22996076
J Vet Pharmacol Ther. 2007 Oct;30(5):477-81
pubmed: 17803742
J Pineal Res. 2003 Sep;35(2):85-90
pubmed: 12887650
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98
pubmed: 19106348
J Clin Pathol. 2001 Mar;54(3):176-86
pubmed: 11253127
Basic Clin Pharmacol Toxicol. 2005 Nov;97(5):325-32
pubmed: 16236146